Widespread Genomic Testing Deemed Feasible.

Abstract excerpt

Although comprehensive genomic screening has not yet become routine when treating patients with cancer, widespread testing in those with advanced, refractory disease is feasible, according to the ongoing ProfiLER study. The study also found that patients who subsequently received a treatment matched to the genetic changes in their tumor lived longer than those who lacked a so-called actionable mutation.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genomics
• Share to High-Throughput Nucleotide Sequencing
• Share to Molecular Targeted Therapy